The MDS Foundation proudly partners with the following organizations
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
4573 South Broad St., Suite 150
Yardville, NJ 08620
A global non-profit advocacy organization, supporting patients, families and healthcare providers in the fields of MDS and its related diseases for over 30 years
© 2024 MDS Foundation. All rights reserved.
December 4, 2020
Advances in Diagnosis & Management of MDS
Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).
Mario Cazzola, MD
Jane Churpek, MD, MS
Stephen D. Nimer, MD
Rafael Bejar, MD, PhD
Stephane de Botton, MD, PhD
Mario Cazzola, MD
Jane Churpek, MD, MS
Amy Elizabeth DeZern, MD, MHS
Saar Gill, MD, PhD
Katharina S. Gotze, MD
Stephen D. Nimer, MD
Access to the meeting outputs are available below by clicking on each topic.
Thank you to AbbVie, Astex Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc, Gamida Cell, Geron Corporation, and Onconova therapeutics for supporting this initiative.
